CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $32.51B, higher than 95% of all stocks globally
- FinancialsAltman Z-Score 1.9: grey zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.23%
Annual Rate
USD 0.16Paid quarterly
Payout Ratio
3.2%Sustainable
Consecutive Growth
2 yr
Paying Dividends
4 yr
Last Ex-Dividend
Oct 23, 2026
Next Payment
Nov 13, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
32.51BUSDvs all stocks (USD)
Trailing P/E
16.43xRevenue (TTM)
21.27BUSDvs all stocks (USD)
Profit Margin
9.33%Beta
0.8480xvs all stocks
52-Week Change
-11.30%vs all stocks
Forward Annual Dividend Yield
0.23%vs all stocks
Market Capitalization
32.51BUSDvs all stocks (USD)
Enterprise Value
40.98BUSDvs all stocks (USD)
Trailing P/E
16.43xForward P/E
13.20xPEG Ratio
0.9673xPrice to Sales (TTM)
1.52xPrice to Book (MRQ)
2.94xEnterprise to Revenue
1.93xEnterprise to EBITDA
11.40xGross Margin
41.16%Profit Margin
9.33%Operating Margin
14.98%Return on Assets (TTM)
5.13%Return on Equity (TTM)
19.38%Revenue (TTM)
21.27BUSDvs all stocks (USD)
Revenue per Share (TTM)
46.79USDUpdated Oct 27, 2026Quarterly Revenue Growth
5.80%Gross Profit (TTM)
8.41BUSDvs all stocks (USD)
EBITDA (TTM)
3.70BUSDvs all stocks (USD)
Net Income (TTM)
1.98BUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
15.40%Operating Cash Flow (TTM)
2.10BUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
1.57BUSDvs all stocks (USD)
Forward Annual Dividend Rate
0.1600USDUpdated Oct 27, 2026Forward Annual Dividend Yield
0.23%vs all stocks
Trailing Annual Dividend Rate
0.1450USDUpdated Oct 27, 2026Trailing Annual Dividend Yield
0.21%vs all stocks
Payout Ratio
3.22%Minority Interest (Equity)
220.00MUSDFY2025 · Dec 31, 2025Revenue
20.63BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
12.38BUSDFY2025 · Dec 31, 2025Gross Profit
8.25BUSDFY2025 · Dec 31, 2025Operating Income
2.76BUSDvs all stocks (USD)
Pre-tax Income
2.77BUSDFY2025 · Dec 31, 2025Income Tax Expense
614.00MUSDFY2025 · Dec 31, 2025Net Income
2.15BUSDFY2025 · Dec 31, 2025EBIT
3.21BUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
3.69BUSDFY2025 · Dec 31, 2025Research & Development
1.26BUSDFY2025 · Dec 31, 2025Selling, General & Administrative
4.22BUSDFY2025 · Dec 31, 2025Non-operating Interest Income
41.00MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
440.00MUSDFY2025 · Dec 31, 2025EPS (Basic)
4.56USDFY2025 · Dec 31, 2025EPS (Diluted)
4.55USDFY2025 · Dec 31, 2025Basic Shares Outstanding
456.00MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
456.00MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
2.15BUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
-70.00MUSDFY2025 · Dec 31, 2025Operating Cash Flow
3.02BUSDFY2025 · Dec 31, 2025Free Cash Flow
2.54BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
4.51BUSDFY2025 · Dec 31, 2025Interest Paid
522.00MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
2.15BUSDFY2025 · Dec 31, 2025Depreciation & Amortization
578.00MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
614.00MUSDFY2025 · Dec 31, 2025Stock-based Compensation
130.00MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-302.00MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-276.00MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
90.00MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
33.00MUSDFY2025 · Dec 31, 2025Capital Expenditures
-482.00MUSDFY2025 · Dec 31, 2025Net Acquisitions
-378.00MUSDFY2025 · Dec 31, 2025Purchase of Investments
-118.00MUSDFY2025 · Dec 31, 2025Other Investing Activity
-69.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.05BUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
2.73BUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.77BUSDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
1.00MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-200.00MUSDFY2025 · Dec 31, 2025Common Dividends Paid
-64.00MUSDFY2025 · Dec 31, 2025Other Financing Charges
-124.00MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
580.00MUSDFY2025 · Dec 31, 2025Shares Outstanding
451.69MSharesUpdated Oct 27, 2026Float Shares
450.20MSharesUpdated Oct 27, 2026Shares Short
18.52MSharesUpdated Oct 27, 2026Short Ratio
5.18daysvs all stocks
Short % of Shares Outstanding
4.65%vs all stocks
% Held by Insiders
0.37%vs all stocks
% Held by Institutions
94.26%vs all stocks
Total Cash (MRQ)
2.08BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.60USDUpdated Oct 27, 2026Total Debt (MRQ)
10.54BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.9396xCurrent Ratio (MRQ)
1.26xBook Value per Share (MRQ)
24.30USDUpdated Oct 27, 2026Total Assets
36.91BUSDvs all stocks (USD)
Total Current Assets
12.50BUSDFY2025 · Dec 31, 2025Total Liabilities
26.31BUSDFY2025 · Dec 31, 2025Total Non-current Assets
24.41BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
17.20BUSDFY2025 · Dec 31, 2025Total Current Liabilities
9.11BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
4.49BUSDFY2025 · Dec 31, 2025Accounts Receivable
3.72BUSDFY2025 · Dec 31, 2025Inventory
2.23BUSDFY2025 · Dec 31, 2025Accounts Payable
3.25BUSDFY2025 · Dec 31, 2025Short-term Debt
642.00MUSDFY2025 · Dec 31, 2025Deferred Revenue
2.10BUSDFY2025 · Dec 31, 2025Other Current Liabilities
651.00MUSDFY2025 · Dec 31, 2025Long-term Debt
9.82BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
203.00MUSDFY2025 · Dec 31, 2025Common Stock (Book)
5.00MUSDFY2025 · Dec 31, 2025Retained Earnings
5.28BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
10.60BUSDvs all stocks (USD)
Treasury Stock
225.00MUSDFY2025 · Dec 31, 202552-Week Low
58.75USDUpdated Oct 27, 202652-Week High
89.77USDUpdated Oct 27, 202652-Week Change
-11.30%vs all stocks
Beta
0.8480xvs all stocks
50-Day MA
68.36USDUpdated Oct 27, 2026200-Day MA
70.12USDUpdated Oct 27, 2026Avg 10-Day Volume
3.19MSharesUpdated Oct 27, 2026Avg 30-Day Volume
3.65MSharesUpdated Oct 27, 2026Diluted EPS (TTM)
4.35USDUpdated Oct 27, 2026Other Income / Expense
404.00MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
Where is this company structurally exposed?
Elevated Leverage on Three Denominators
Debt sits high against its equity, its assets, and its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 1.9: grey zoneSignificant
Altman Z-Score: 1.90
High earnings qualityNotable
Earnings Quality Score: 1.06
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $32.51B, higher than 95% of all stocks globallySignificant
Market cap (USD): 32,512,376,418Global P95: 25,994,381,698
Revenue is $21.27B, higher than 95% of all stocks globallySignificant
Revenue (USD): 21,265,999,872Global P95: 15,439,399,680
Levered free cash flow is $1.57B, higher than 95% of all stocks globallySignificant
Levered free cash flow (USD): 1,573,124,992Global P95: 1,233,976,520.5
Companies that share the same coordination system — how they create, deliver, or capture value.
Zoetis Inc.
Tier 1ProductionApproval-Gated PipelineRule
Celltrion Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hansoh Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alnylam Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Dexcom Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Biogen Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Revolution Medicines Inc.
Tier 1ProductionApproval-Gated PipelineRule
Roivant Sciences Ltd
Tier 1ProductionApproval-Gated PipelineRuleRisk
Koninklijke Philips N.V.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Nippon Telegraph and Telephone Corporation
2 interpretationsElevated Leverage on Three DenominatorsMulti-Year Revenue, Profit, And Income Growth
Warner Music Group Corp.
2 interpretationsElevated Leverage on Three DenominatorsMulti-Year Revenue, Profit, And Income Growth
Waste Management, Inc.
2 interpretationsElevated Leverage on Three DenominatorsMulti-Year Revenue, Profit, And Income Growth